NeOnc Technologies Holdings (NTHI) said Monday that the US Food and Drug Administration has granted rare pediatric disease designation to perillyl alcohol, also known as NEO100, for the treatment of pediatric-type diffuse high-grade gliomas.
The company said the FDA designation was based on findings that pediatric-type diffuse high-grade gliomas meets the statutory definition of a rare disease or condition.
According to NeOnc Technologies, the designation makes it eligible to receive a priority review voucher upon approval of the marketing application for perillyl alcohol. The program is meant to encourage development of new treatments for rare pediatric diseases by providing an expedited regulatory review process.
Shares of NeOnc Technologies Holdings were down more than 24% in recent Monday trading.
Price: 12.00, Change: -5.00, Percent Change: -29.41
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。